Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception.
OBJECTIVE
To evaluate the efficacy and safety of ulipristal acetate as emergency contraception in women presenting 48-120 hours after receiving ulipristal acetate for unprotected intercourse.


METHODS
Women aged 18 years or older with regular cycles who presented for emergency contraception 48 to 120 hours after unprotected intercourse were enrolled in 45 Planned Parenthood clinics and treated with a single dose of 30 mg ulipristal acetate. Pregnancy status was determined by high-sensitivity urinary human chorionic gonadotropin testing and return of menses.


RESULTS
A total of 1,241 women were evaluated for efficacy. Twenty-six were pregnant at follow-up, for a pregnancy rate of 2.1% (95% confidence interval 1.4-3.1%). These results satisfy the protocol-defined statistical criteria for success because the pregnancy rate was lower than both the estimated expected pregnancy rate and a predefined clinical irrelevance threshold. In addition, efficacy did not decrease over time: pregnancy rates were 2.3% (1.4-3.8%), 2.1% (1.0-4.1%), and 1.3% (0.1-4.8%) for intervals of 48 to 72 hours, more than 72 to 96 hours, and more than 96 to 120 hours, respectively. Adverse events were mainly mild or moderate, the most frequent being headache, nausea, and abdominal pain. Cycle length increased a mean of 2.8 days, whereas the duration of menstrual bleeding did not change.


CONCLUSIONS
Ulipristal acetate is effective and well-tolerated for emergency contraception 48-120 hours after unprotected intercourse.


METHODS
II.
Fine
Paul
P
From Planned Parenthood of Houston & Southeast Texas, Houston, Texas; HRA Pharma, Paris, France; Planned Parenthood of the Rocky Mountains, Denver, Colorado; and Planned Parenthood Federation of America, New York, New York.
Mathé
Henri
H
Ginde
Savita
S
Cullins
Vanessa
V
Morfesis
Johanna
J
Gainer
Erin
E
D044363:Contraception, Postcoital / Q000009:adverse effects; D003282:Contraceptives, Postcoital, Hormonal / Q000009:adverse effects; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D009649:Norpregnadienes; D011247:Pregnancy
D003282:Contraceptives, Postcoital, Hormonal; D009649:Norpregnadienes; C094854:ulipristal; C555622:ulipristal acetate